Preventing low white blood cell fever during cancer chemotherapy
Part of Cancer clinical trials.
This study compares different doses of a medication called PEG-rhG-CSF, which is used to help prevent a serious side effect of chemotherapy called febrile neutropenia (fever with a low white blood cell count). The goal is to find the best dose that keeps your blood counts healthy and reduces the risk of infection during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a confirmed cancer diagnosis (by biopsy or other lab test).
- You are able to receive chemotherapy and are expected to tolerate several treatment cycles.
- You are generally well enough to handle daily activities (a performance score of 70 or higher).
- Your blood counts are within normal ranges (white blood cells, red blood cells, and platelets) before starting.
- You have not had chemotherapy or radiation in the last 6 months.
- You have never used a white blood cell booster such as Neulasta or Neupogen before.
- Your cancer has not spread to your bone marrow, and you have not had a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This study tests a drug (me capegfilgrastim) given as a shot to help prevent a dangerous drop in white blood cells and fever during chemotherapy. It is for people with cancer who are at high risk for this side effect.
This trial looks at whether adding a medicine called G-CSF (which helps the body make more white blood cells) to antibiotics is better than antibiotics alone for children with cancer who develop a fever and low blood cell counts after chemotherapy.
This study looks at whether a common side effect (bone pain) from a medicine that boosts white blood cells (called G-CSF) is related to the number of neutrophils (a type of white blood cell) in your blood. If you join, you will receive the medicine as part of your normal chemotherapy routine, and the researchers will track your blood counts and any bone pain you experience.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.